Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is an unmet clinical challenge due to the rapid increased occurrence but lacking approved drugs. Autophagy-related protein 16-like 1 (ATG16L1) plays an important role in the process of autophagy, which is indispensable for proper biogenesis of the autophagosome, but its role in modulating macrophage-related inflammation and metabolism during MASH has not been documented. Here, we aimed to elucidate the role of ATG16L1 in the progression of MASH. Methods: Expression analysis was performed with liver samples from human and mice. MASH models were induced in myeloid-specific Atg16l1-deficient and myeloid-specific Atg16l1-overexpressed mice by high-fat and highcholesterol diet or methionine- and choline-deficient diet to explore the function and mechanism of macrophage ATG16L1 in MASH. Results: Macrophage-specific Atg16l1 knockout exacerbated MASH and inhibited energy expenditure, whereas macrophage-specific Atg16l1 transgenic overexpression attenuated MASH and promotes energy expenditure. Mechanistically, Atg16l1 knockout inhibited macrophage lipophagy, thereby suppressing macrophage β-oxidation and decreasing the production of 4-hydroxynonenal, which further inhibited stimulator of interferon genes (STING) carbonylation. STING palmitoylation was enhanced, STING trafficking from the endoplasmic reticulum to the Golgi was promoted, and downstream STING signaling was activated, promoting proinflammatory and profibrotic cytokines secretion, resulting in hepatic steatosis and hepatic stellate cells activation. Moreover, Atg16l1-deficiency enhanced macrophage phagosome ability but inhibited lysosome formation, engulfing mtDNA released by pyroptotic hepatocytes. Increased mtDNA promoted cGAS/STING signaling activation. Moreover, pharmacological promotion of ATG16L1 substantially blocked MASH progression. Conclusions: ATG16L1 suppresses MASH progression by maintaining macrophage lipophagy, restraining liver inflammation, and may be a promising therapeutic target for MASH management.
Abstract
Background/Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is an unmet clinical challenge due to the rapid increased occurrence but lacking approved drugs. Autophagy-related protein 16-like 1 (ATG16L1) plays an important role in the process of autophagy, which is indispensable for proper biogenesis of the autophagosome, but its role in modulating macrophage-related inflammation and metabolism during MASH has not been documented. Here, we aimed to elucidate the role of ATG16L1 in the progression of MASH. Methods: Expression analysis was performed with liver samples from human and mice. MASH models were induced in myeloid-specific Atg16l1-deficient and myeloid-specific Atg16l1-overexpressed mice by high-fat and highcholesterol diet or methionine- and choline-deficient diet to explore the function and mechanism of macrophage ATG16L1 in MASH. Results: Macrophage-specific Atg16l1 knockout exacerbated MASH and inhibited energy expenditure, whereas macrophage-specific Atg16l1 transgenic overexpression attenuated MASH and promotes energy expenditure. Mechanistically, Atg16l1 knockout inhibited macrophage lipophagy, thereby suppressing macrophage β-oxidation and decreasing the production of 4-hydroxynonenal, which further inhibited stimulator of interferon genes (STING) carbonylation. STING palmitoylation was enhanced, STING trafficking from the endoplasmic reticulum to the Golgi was promoted, and downstream STING signaling was activated, promoting proinflammatory and profibrotic cytokines secretion, resulting in hepatic steatosis and hepatic stellate cells activation. Moreover, Atg16l1-deficiency enhanced macrophage phagosome ability but inhibited lysosome formation, engulfing mtDNA released by pyroptotic hepatocytes. Increased mtDNA promoted cGAS/STING signaling activation. Moreover, pharmacological promotion of ATG16L1 substantially blocked MASH progression. Conclusions: ATG16L1 suppresses MASH progression by maintaining macrophage lipophagy, restraining liver inflammation, and may be a promising therapeutic target for MASH management.
참고문헌 (50)
- Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
- Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol, 79, pp.1542~1556 (2023)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- Loomba R, "Mechanisms and disease consequences of nonalcoholic fatty liver disease", Cell, 184, pp.2537~2564 (2021)
- Spengler EK, "Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Mayo Clin Proc, 90, pp.1233~1246 (2015)
- Wong VW, "Pathogenesis and novel treatment options for non-alcoholic steatohepatitis", Lancet Gastroenterol Hepatol, 1, pp.56~67 (2016)
- Mizushima N, "Autophagy fights disease through cellular self-digestion", Nature, 451, pp.1069~1075 (2008)
- Shintani T, "Autophagy in health and disease : a double-edged sword", Science, 306, pp.990~995 (2004)
- Weiskirchen R, "Relevance of Autophagy in parenchymal and non-parenchymal liver cells for health and disease", Cells, 8, pp.16~ (2019)
- Tacke F, "Targeting hepatic macrophages to treat liver diseases", J Hepatol, 66, pp.1300~1312 (2017)
- Lodder J, "Macrophage autophagy protects against liver fibrosis in mice", Autophagy, 11, pp.1280~1292 (2015)
- Gual P, "Autophagy in chronic liver diseases : the two faces of Janus", Am J Physiol Cell Physiol, 312, pp.C263~C273 (2017)
- Allaire M, "Autophagy in liver diseases : time for translation?", J Hepatol, 70, pp.985~998 (2019)
- Gilgenkrantz H, "Targeting cell-intrinsic metabolism for antifibrotic therapy", J Hepatol, 74, pp.1442~1454 (2021)
- Matsuzawa-Ishimoto Y, "Autophagy and inflammation", Annu Rev Immunol, 36, pp.73~101 (2018)
- Li Y, "Intracellular C3prevents hepatic steatosis by promoting autophagy and verylow-density lipoprotein secretion", FASEB J, 35, pp.e22037~ (2021)
- Okada H, "Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet", Oncotarget, 8, pp.39978~39993 (2017)
- Wang Q, "Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis", J Hepatol, 77, pp.312~325 (2022)
- Zhou H, "Glycogen synthase kinase 3β promotes liver innate immune activation by restraining AMP-activated protein kinase activation", J Hepatol, 69, pp.99~109 (2018)
- Koh EH, "Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis", Gut, 70, pp.1954~1964 (2021)
- Yu Y, "STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis", J Clin Invest, 129, pp.546~555 (2019)
- Loomba R, "Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH", Hepatology, 73, pp.625~643 (2021)
- Brasaemle DL, "Perilipin A increases triacylglycerol storage by decreasing the rate of triacylglycerol hydrolysis", J Biol Chem, 275, pp.38486~38493 (2000)
- Hoppel C, "Riboflavin and rat hepatic cell structure and function. Mitochondrial oxidative metabolism in deficiency states", J Biol Chem, 254, pp.4164~4170 (1979)
- Kaushik S, "Lysosome membrane lipid microdomains : novel regulators of chaperone-mediated autophagy", EMBO J, 25, pp.3921~3933 (2006)
- Huai W, "Mint3 potentiates TLR3", 4-and RIG-I-induced IFN-β expression and antiviral immune responses, 2016, pp.113, 11925~11930
- Chao CC, "Modification of protein surface hydrophobicity and methionine oxidation by oxidative systems", Proc Natl Acad Sci U S A, 94, pp.2969~2974 (1997)
- van der Klaauw AA, "Human semaphorin 3 variants link melanocortin circuit development and energy balance", Cell, 176, pp.729~742 (2019)
- Ko MS, "Mitophagy deficiency increases NLRP3 to induce brown fat dysfunction in mice", Autophagy, 17, pp.1205~1221 (2021)
- Szklarczyk D, "Protein-protein interaction databases", Methods Mol Biol, 1278, pp.39~56 (2015)
- Chao X, "Impaired TFEB-mediated lysosome biogenesis and autophagy promote chronic ethanol-induced liver injury and steatosis in mice", Gastroenterology, 155, pp.865~879 (2018)
- Dobbs N, "STING activation by translocation from the ER is associated with infection and autoinflammatory disease", Cell Host Microbe, 18, pp.157~168 (2015)
- Li N, "STINGIRF3contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3", Redox Biol, 24, pp.101215~ (2019)
- Liu Z, "XBP1 deficiency promotes hepatocyte pyroptosis by impairing mitophagy to activate mtDNA-cGAS-STING signaling in macrophages during acute liver injury", Redox Biol, 52, pp.102305~ (2022)
- Garcia-Martinez I, "Therapeutic opportunities in damage-associated molecular pattern-driven metabolic diseases", Antioxid Redox Signal, 23, pp.1305~1315 (2015)
- Luo X, "Expression of STING is increased in liver tissues from patients with NAFLD and promotes macrophage-mediated hepatic inflammation and fibrosis in mice", Gastroenterology, 155, pp.1971~1984 (2018)
- Schattenberg JM, "JNK1 but not JNK2 promotes the development of steatohepatitis in mice", Hepatology, 43, pp.163~172 (2006)
- Cadwell K, "A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells", Nature, 456, pp.259~263 (2008)
- Kuma A, "Formation of the approximately 350-kDa Apg12-Apg5. Apg16 multimeric complex, mediated by Apg16 oligomerization, is essential for autophagy in yeast", J Biol Chem, 277, pp.18619~18625 (2002)
- Qian H, "Autophagy in liver diseases : a review", Mol Aspects Med, 82, pp.100973~ (2021)
- Singh R, "Autophagy regulates lipid metabolism", Nature, 458, pp.1131~1135 (2009)
- Thoen LF, "A role for autophagy during hepatic stellate cell activation", J Hepatol, 55, pp.1353~1360 (2011)
- Jia M, "Redox homeostasis maintained by GPX4 facilitates STING activation", Nat Immunol, 21, pp.727~735 (2020)
- Ding L, "Peroxisomal β-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis", Nat Metab, 3, pp.1648~1661 (2021)
- Mukai K, "Activation of STING requires palmitoylation at the Golgi", Nat Commun, 7, pp.11932~ (2016)
- Li R, "1, 25(OH)2 D3attenuates hepatic steatosis by inducing autophagy in mice", Obesity(Silver Spring), 25, pp.561~571 (2017)
- Remmerie A, "Macrophages and lipid metabolism", Cell Immunol, 330, pp.27~42 (2018)
- Wolfkamp SC, "ATG16L1 and NOD2 polymorphisms enhance phagocytosis in monocytes of Crohn’s disease patients", World J Gastroenterol, 20, pp.2664~2672 (2014)
- Srikanth S, "The Ca2+ sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum", Nat Immunol, 20, pp.152~162 (2019)
- Ishikawa H, "STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity", Nature, 461, pp.788~792 (2009)